Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- New Year's superstitions: Eating 12 grapes, avoiding laundry and other rituals that are said to bring good fortune
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- The Secret Destinations Amex Says Will Be More Popular Than Bali by 2026
- Zelensky warns of imminent massive Russian attack on Ukraine
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
